GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz™

Autor: PR Newswire
Zdroj: PR Newswire US. 12/11/2024.
Abstrakt: ** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the Emergency Room ** [ABSTRACT FROM PUBLISHER]
Databáze: Regional Business News
Nepřihlášeným uživatelům se plný text nezobrazuje